Skip to main content

Table 2 Adverse events

From: Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting

Toxicity T + C (n = 50) T (n = 67)
Any ≥3 Any ≥3
Skin rash 32(64.00%) 2(4.00%) 47(70.15%) 2(2.99%)
Elevated AST / ALT 31(62.00%) 6(12.00%) 34(50.74%) 7(10.45%)
Diarrhoea 19(38.00%) 1(2.00%) 24(35.82%) 1(1.49%)
Leukopenia / Neutropenia 22(44.00%) 7(14.00%) 5(7.46%) 0(0.00%)
Anaemia 19(38.00%) 5(10.00%) 6(8.96%) 0(0.00%)
Thrombocytopenia 17(34.00%) 6(12.00%) 6(8.96%) 0(0.00%)
Nausea / Vomiting 14(28.00%) 2(4.00%) 7(10.45%) 0(0.00%)
Fatigue 16(32.00%) 2(4.00%) 5(7.46%) 0(0.00%)
Anorexia 15(30.00%) 2(4.00%) 710.45%) 1(1.49%)
Mucositis 12(24.00%) 1(1.23%) 9(13.43%) 1(1.49%)
Constipation 10(20.00%) 0(0.00%) 7(10.45%) 0(0.00%)